CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Percutaneous Support Devices for Percutaneous Coronary Intervention Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study Considerations for Single-Measurement Risk-Stratification Strategies for Myocardial Infarction Using Cardiac Troponin Assays Burden of 30-Day Readmissions After Percutaneous Coronary Intervention in 833,344 Patients in the United States: Predictors, Causes, and Cost Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data

JOURNAL:FDA Article Link

美国食品和药品管理局发布加强医疗设备安全与创新管理的最新举措

FDA Commissioner Scott Gottlieb


    自2018年4月17日生效的、由美国食品和药品管理局发布的《关于加强医疗设备安全与创新管理的最新举措的声明》中指出,医疗器械创新对健康促进的贡献已史无前例,其中所涉及的材料学、数字技术和高级制造三个领域正面临不均衡的发展现状。尽管去年获FDA批准的创新型准入器械数量达到了历史新高,但因缺乏排除隐患所需的临床证据而亟需FDA采用新的监管手段加以规范。


    FDA此次推出的“行动计划”Medical Device Safety Action Plan: Protecting Patients, Promoting Public Health”主要涉及五个领域:


  1. 1. 在美国建立健全医疗设备患者安全网络;
  2. 2. 探索高效、与时俱进的现代化准入后管理办法;
  3. 3. 鼓励发展更高安全级别的创新;
  4. 4. 推进医疗器械网络安全;
  5. 5. 重新整合FDA设备和放射卫生中心(FDA’s Center for Devices and Radiological Health)的准入前后管理分工并进一步推动产品全生命周期(Total Product Life Cycle, TPLC)设备安全管理法。


文献

1. Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to enhance and modernize the FDA’s approach to medical device safety and innovation

2. Medical Device Safety Action Plan: Protecting Patients, Promoting Public Health


转发或引用此篇新闻稿中文版内容,请注明CBSMD。